• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转录因子和甲基化驱动肝细胞癌中预后性微小RNA的失调

Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma.

作者信息

Qin Shijie, Xu Jieyun, Yi Yunmeng, Jiang Sizhu, Jin Ping, Xia Xinyi, Ma Fei

机构信息

Laboratory for Comparative Genomics and Bioinformatics & Jiangsu Key Laboratory for Biodiversity and Biotechnology, College of Life Science, Nanjing Normal University, Nanjing, China.

Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, The First School of Clinical Medicine, Southern Medical University, Nanjing, China.

出版信息

Front Oncol. 2021 Jul 1;11:691115. doi: 10.3389/fonc.2021.691115. eCollection 2021.

DOI:10.3389/fonc.2021.691115
PMID:34307154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8297977/
Abstract

Many dysregulated microRNAs (miRNAs) have been suggested to serve as oncogenes or tumor suppressors to act as diagnostic and prognostic factors for HCC patients. However, the dysregulated mechanisms of miRNAs in HCC remain largely unknown. Herein, we firstly identify 114 disordered mature miRNAs in HCC, 93 of them are caused by dysregulated transcription factors, and 10 of them are driven by the DNA methylation of their promoter regions. Secondly, we find that seven up-regulated miRNAs (miR-9-5p, miR-452-5p, miR-452-3p, miR-1180-3p, miR-4746-5p, miR-3677-3 and miR-4661-5p) can promote tumorigenesis inhibiting multiple tumor suppressor genes participated in metabolism, which may act as oncogenes, and seven down-regulated miRNAs (miR-99-5p, miR-5589-5p, miR-5589-3p, miR-139-5p, miR-139-3p, miR-101-3p and miR-125b-5p) can suppress abnormal cell proliferation suppressing a number of oncogenes involved in cancer-related pathways, which may serve as tumor suppressors. Thirdly, our findings reveal a mechanism that transcription factor and miRNA interplay can form various regulatory loops to synergistically control the occurrence and development of HCC. Finally, our results demonstrate that this key transcription factor FOXO1 can activate a certain number of tumor suppressor miRNAs to improve the survival of HCC patients, suggesting FOXO1 as an effective therapeutic target for HCC patients. Overall, our study not only reveals the dysregulated mechanisms of miRNAs in HCC, but provides several novel prognostic biomarkers and potential therapeutic targets for HCC patients.

摘要

许多失调的微小RNA(miRNA)被认为可作为癌基因或肿瘤抑制因子,充当肝癌患者的诊断和预后因素。然而,miRNA在肝癌中的失调机制仍 largely未知。在此,我们首先在肝癌中鉴定出114个失调的成熟miRNA,其中93个由转录因子失调引起,10个由其启动子区域的DNA甲基化驱动。其次,我们发现7个上调的miRNA(miR-9-5p、miR-452-5p、miR-452-3p、miR-1180-3p、miR-4746-5p、miR-3677-3和miR-4661-5p)可通过抑制参与代谢的多个肿瘤抑制基因促进肿瘤发生,这些miRNA可能充当癌基因,7个下调的miRNA(miR-99-5p、miR-5589-5p、miR-5589-3p、miR-139-5p、miR-139-3p、miR-101-3p和miR-125b-5p)可通过抑制参与癌症相关途径的多个癌基因抑制异常细胞增殖,这些miRNA可能充当肿瘤抑制因子。第三,我们的研究结果揭示了一种机制,即转录因子和miRNA相互作用可形成各种调控环,协同控制肝癌的发生和发展。最后,我们的结果表明,这个关键转录因子FOXO1可激活一定数量的肿瘤抑制miRNA以提高肝癌患者的生存率,提示FOXO1作为肝癌患者的有效治疗靶点。总体而言,我们的研究不仅揭示了miRNA在肝癌中的失调机制,还为肝癌患者提供了几个新的预后生物标志物和潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/cba7bb312a0e/fonc-11-691115-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/8801a21750df/fonc-11-691115-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/03128339df8c/fonc-11-691115-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/4b5422744500/fonc-11-691115-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/81a30417fdf2/fonc-11-691115-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/d1c5fd847471/fonc-11-691115-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/cba7bb312a0e/fonc-11-691115-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/8801a21750df/fonc-11-691115-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/03128339df8c/fonc-11-691115-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/4b5422744500/fonc-11-691115-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/81a30417fdf2/fonc-11-691115-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/d1c5fd847471/fonc-11-691115-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5e/8297977/cba7bb312a0e/fonc-11-691115-g006.jpg

相似文献

1
Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma.转录因子和甲基化驱动肝细胞癌中预后性微小RNA的失调
Front Oncol. 2021 Jul 1;11:691115. doi: 10.3389/fonc.2021.691115. eCollection 2021.
2
Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles.基于 miRNA 表达谱鉴定肝癌的预后标志物。
Life Sci. 2019 Sep 1;232:116596. doi: 10.1016/j.lfs.2019.116596. Epub 2019 Jun 22.
3
Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.循环 microRNAs 作为肝细胞癌潜在的诊断和预后生物标志物。
Sci Rep. 2019 Jul 18;9(1):10464. doi: 10.1038/s41598-019-46872-8.
4
Diagnostic value of strand-specific miRNA-101-3p and miRNA-101-5p for hepatocellular carcinoma and a bioinformatic analysis of their possible mechanism of action.链特异性miRNA-101-3p和miRNA-101-5p对肝细胞癌的诊断价值及其可能作用机制的生物信息学分析
FEBS Open Bio. 2017 Dec 20;8(1):64-84. doi: 10.1002/2211-5463.12349. eCollection 2018 Jan.
5
MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion.miR-493-5p 通过抑制 MYCN 癌基因抑制肝癌细胞生长和侵袭。
Cancer Sci. 2020 Mar;111(3):869-880. doi: 10.1111/cas.14292. Epub 2020 Jan 25.
6
Transcription Factor and miRNA Interplays Can Manifest the Survival of ccRCC Patients.转录因子与微小RNA的相互作用能够体现肾透明细胞癌患者的生存率。
Cancers (Basel). 2019 Oct 28;11(11):1668. doi: 10.3390/cancers11111668.
7
[Roles of miR-590-5p and miR-590-3p in the development of hepatocellular carcinoma].[miR-590-5p和miR-590-3p在肝细胞癌发生发展中的作用]
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Jun;33(6):804-11.
8
MicroRNA profile in HBV-induced infection and hepatocellular carcinoma.HBV 诱导感染和肝细胞癌中的 microRNA 谱。
BMC Cancer. 2017 Dec 1;17(1):805. doi: 10.1186/s12885-017-3816-1.
9
Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.血浆 miRNA 作为检测肝细胞癌的早期生物标志物。
Int J Cancer. 2015 Oct 1;137(7):1679-90. doi: 10.1002/ijc.29544. Epub 2015 Apr 21.
10
Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma.循环 miRNA-223-3p 在乙型肝炎病毒相关肝细胞癌中的诊断和预后作用。
PLoS One. 2020 Apr 24;15(4):e0232211. doi: 10.1371/journal.pone.0232211. eCollection 2020.

引用本文的文献

1
Current updates regarding biogenesis, functions and dysregulation of microRNAs in cancer: Innovative approaches for detection using CRISPR/Cas13‑based platforms (Review).癌症中微小RNA的生物发生、功能及失调的最新进展:基于CRISPR/Cas13平台的创新检测方法(综述)
Int J Mol Med. 2025 Jun;55(6). doi: 10.3892/ijmm.2025.5531. Epub 2025 Apr 17.
2
LncRNA PTENP1/miR-21/PTEN Axis Modulates EMT and Drug Resistance in Cancer: Dynamic Boolean Modeling for Cell Fates in DNA Damage Response.LncRNA PTENP1/miR-21/PTEN 轴调控癌症中的 EMT 和耐药性:DNA 损伤反应中细胞命运的动态布尔建模。
Int J Mol Sci. 2024 Jul 29;25(15):8264. doi: 10.3390/ijms25158264.
3

本文引用的文献

1
Forkhead Box Protein O1: Functional Diversity and Post-Translational Modification, a New Therapeutic Target?叉头框蛋白 O1:功能多样性和翻译后修饰,新的治疗靶点?
Drug Des Devel Ther. 2021 May 3;15:1851-1860. doi: 10.2147/DDDT.S305016. eCollection 2021.
2
Serum Biomarkers for the Prediction of Hepatocellular Carcinoma.用于预测肝细胞癌的血清生物标志物
Cancers (Basel). 2021 Apr 2;13(7):1681. doi: 10.3390/cancers13071681.
3
Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Elucidating hepatocellular carcinoma progression: a novel prognostic miRNA-mRNA network and signature analysis.
阐明肝细胞癌的进展:一种新的预后 miRNA-mRNA 网络和特征分析。
Sci Rep. 2024 Feb 29;14(1):5042. doi: 10.1038/s41598-024-55806-y.
4
Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with Variant rs27770A>G.hsa-miR-100-5p表达增加改善了亚洲人群中rs27770A>G变异型肝细胞癌的预后。
Cancers (Basel). 2023 Dec 27;16(1):129. doi: 10.3390/cancers16010129.
5
Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.2021 年高发性癌症的 microRNAs 作为诊断和预后生物标志物概述。
Int J Mol Sci. 2022 Sep 27;23(19):11389. doi: 10.3390/ijms231911389.
6
MicroRNA-let-7 Targets HMGA2 to Regulate the Proliferation, Migration, and Invasion of Colon Cancer Cell HCT116.微小RNA-let-7靶向HMGA2以调控结肠癌细胞HCT116的增殖、迁移和侵袭。
Evid Based Complement Alternat Med. 2021 Sep 15;2021:2134942. doi: 10.1155/2021/2134942. eCollection 2021.
腹部超声和甲胎蛋白检测用于诊断慢性肝病成人的肝细胞癌。
Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013346. doi: 10.1002/14651858.CD013346.pub2.
4
Genetic variation and microRNA targeting of A-to-I RNA editing fine tune human tissue transcriptomes.A-to-I RNA 编辑的遗传变异和 microRNA 靶向微调人类组织转录组。
Genome Biol. 2021 Mar 9;22(1):77. doi: 10.1186/s13059-021-02287-1.
5
MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review.微小RNA在肝细胞癌发病机制中的研究进展:综述
Cancers (Basel). 2021 Jan 29;13(3):514. doi: 10.3390/cancers13030514.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.微小 RNA 作为肝脏疾病的调控因子、生物标志物和治疗靶点。
Gut. 2021 Apr;70(4):784-795. doi: 10.1136/gutjnl-2020-322526. Epub 2020 Oct 30.
8
Pan-cancer analysis of somatic mutations in miRNA genes.癌症中 miRNA 基因体细胞突变的泛癌分析。
EBioMedicine. 2020 Nov;61:103051. doi: 10.1016/j.ebiom.2020.103051. Epub 2020 Oct 7.
9
Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets.乙型肝炎病毒相关肝细胞癌中失调的微小RNA:作为生物标志物和治疗靶点的潜力
Front Oncol. 2020 Jul 28;10:1271. doi: 10.3389/fonc.2020.01271. eCollection 2020.
10
Epidemiology of Hepatocellular Carcinoma.肝细胞癌的流行病学
Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288. Epub 2020 Nov 24.